Timber Pharmaceuticals Provides Business Update and Announces Third Quarter 2020 Financial Results
November 12, 2020 16:53 ET
|
Timber Pharmaceuticals
WOODCLIFF LAKE, NJ, Nov. 12, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the...
Timber Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for BPX-01 and BPX-04
September 15, 2020 08:00 ET
|
Timber Pharmaceuticals
- Formal notice confirms intent to grant patent for pharmaceutical tetracycline compositions for dermatological use - WOODCLIFF LAKE, N.J., Sept. 15, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --...
Timber Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference
September 11, 2020 16:29 ET
|
Timber Pharmaceuticals
Virtual Presentation on Wednesday, September 16th at 12:30 PM ET WOODCLIFF LAKE, NJ, Sept. 11, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire-- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”)...
imber Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference
September 11, 2020 16:05 ET
|
Timber Pharmaceuticals
Virtual Presentation on Wednesday, September 16th at 12:30 PM ET WOODCLIFF LAKE, NJ, Sept. 11, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”)...
Timber Pharmaceuticals Announces Appointment of Dr. David Cohen and Dr. Lubor Gaal to Board of Directors
August 19, 2020 16:10 ET
|
Timber Pharmaceuticals
WOODCLIFF LAKE, NJ, Aug. 19, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the...
Timber Pharmaceuticals Provides Business Update and Announces Second Quarter 2020 Financial Results
August 18, 2020 16:10 ET
|
Timber Pharmaceuticals
Phase 2b Clinical Trials for Each of the Company’s Lead Assets in Orphan Dermatologic Diseases are Progressing as Planned WOODCLIFF LAKE, NJ, Aug. 18, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --...
Timber Pharmaceuticals Announces European Patent Office Intends to Grant Patent for BPX-01 and BPX-04
July 22, 2020 08:00 ET
|
Timber Pharmaceuticals
Stable topical composition has potential to reduce side effects of orally delivered compositions in treatment of acne and rosacea WOODCLIFF LAKE, NJ, July 22, 2020 (GLOBE NEWSWIRE) -- via...
Timber Pharmaceuticals Announces All CONTROL Study Sites Open and Enrolling Patients with Moderate to Severe Congenital Ichthyosis
July 01, 2020 08:00 ET
|
Timber Pharmaceuticals
- Phase 2b CONTROL study is evaluating TMB-001 (topical isotretinoin) in subtypes of rare genetic keratinization disorder - - Company also advancing Phase 2b clinical trial evaluating TMB-002...
Timber Pharmaceuticals Announces Appointment of Dr. Gianluca Pirozzi and Edward J. Sitar to Board of Directors
June 04, 2020 08:00 ET
|
Timber Pharmaceuticals
Decades of experience in drug development and finance to support company advancing novel treatments for rare dermatologic diseases Woodcliff Lake, NJ, June 04, 2020 (GLOBE NEWSWIRE) -- via...
Timber Pharmaceuticals to Present at the Virtual Summer Summit
June 03, 2020 08:00 ET
|
Timber Pharmaceuticals
Presentation on Tuesday, June 9th at 2:10pm ET WOODCLIFF LAKE, NJ, June 03, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE...